NXL Nexalin Technology, Inc.
Debt Financing ·
The unsecured note carries a $150,000.00 original issue discount and a $20,000.00 transaction expense amount. The purchase price is $1,000,000.00, and the lender is Streeterville Capital, LLC.
We have not published a story on Nexalin Technology yet. When there is news, it will appear here.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $301,647 | $168,721 |
| Research and development | $1.1 million | $1.2 million |
| Net income (loss) | -$8.2 million | -$7.6 million |
| Cash from operations | -$5.0 million | -$3.9 million |
| Cash and equivalents | $654,783 | $574,485 |
| Short-term investments | $3.1 million | $2.9 million |
Nexalin Technology, Inc. trades under the ticker NXL on NASDAQ.
Nexalin Technology, Inc. is listed on NASDAQ.
Our directory records Nexalin Technology, Inc. under United States.
aibio.space lists Nexalin Technology, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
$301,647 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Nexalin Technology, Inc. reported a net loss of $8.2 million for the fiscal year ended Dec 31, 2025, and used $5.0 million of cash in operations, per its annual report to the SEC.
$1.1 million in the fiscal year ended Dec 31, 2025, per its annual report.
$1.0 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Nexalin Technology, dated Aug 21, 2026: "Nexalin issues $1,170,000.00 promissory note to Streeterville Capital". The unsecured note carries a $150,000.00 original issue discount and a $20,000.00 transaction expense amount. The purchase price is $1,000,000.00, and the lender is Streeterville Capital, LLC. Source.
Our latest debt story, dated Aug 21, 2026: "Nexalin issues $1,170,000.00 promissory note to Streeterville Capital". The unsecured note carries a $150,000.00 original issue discount and a $20,000.00 transaction expense amount. The purchase price is $1,000,000.00, and the lender is Streeterville Capital, LLC. Source.
Press Follow on this page to add Nexalin Technology to your Following list, or subscribe to the aibio.space newsletter. We have published 1 story naming Nexalin Technology so far, in Debt Financing.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,7.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio